Supplements

This supplement to Neurology Reviews compiles news briefs from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, and the 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in West Palm Beach, Florida. 

Click here to read the supplement

This supplement to Neurology Reviews compiles news briefs from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, and the 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in West Palm Beach, Florida. 

Click here to read the supplement

This supplement to Neurology Reviews compiles news briefs from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, and the 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in West Palm Beach, Florida. 

Click here to read the supplement

Click here to read the content.

USA-334-83757

Click here to read the content.

USA-334-83757

Click here to read the content.

USA-334-83757

Click to read.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that affects approximately 10% of US children. Colloidal oatmeal has long been used as a topical treatment for AD and modern research confirms the benefits of colloidal oatmeal formulations to significantly improve symptoms. Click to learn more about colloidal oatmeal in combination with oat flour and oat extract as effective and well-tolerated skin-directed therapy for your young AD patients. 

Click to read. 

About the Author

Click to read.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that affects approximately 10% of US children. Colloidal oatmeal has long been used as a topical treatment for AD and modern research confirms the benefits of colloidal oatmeal formulations to significantly improve symptoms. Click to learn more about colloidal oatmeal in combination with oat flour and oat extract as effective and well-tolerated skin-directed therapy for your young AD patients. 

Click to read. 

About the Author

Click to read.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that affects approximately 10% of US children. Colloidal oatmeal has long been used as a topical treatment for AD and modern research confirms the benefits of colloidal oatmeal formulations to significantly improve symptoms. Click to learn more about colloidal oatmeal in combination with oat flour and oat extract as effective and well-tolerated skin-directed therapy for your young AD patients. 

Click to read. 

About the Author

Click to Read 

With newly available disease-modifying therapies, the phenotype of spinal muscular atrophy (SMA) is rapidly changing, and affected individuals are living longer, healthier lives.^1-4 This supplement discusses therapeutic strategies, FDA-approved treatment options, and the SMA drug pipeline.

Click to Read

To access Part 1 of the SMA Spotlight series, The Urgent Need for Early Diagnosis in Spinal Muscular Atrophy, visit www.mdedge.com/DiagnosisInSMA.

References

1. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732.
2. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625-635.
3. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose genereplacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722.
4. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856.

Click to Read 

With newly available disease-modifying therapies, the phenotype of spinal muscular atrophy (SMA) is rapidly changing, and affected individuals are living longer, healthier lives.^1-4 This supplement discusses therapeutic strategies, FDA-approved treatment options, and the SMA drug pipeline.

Click to Read

To access Part 1 of the SMA Spotlight series, The Urgent Need for Early Diagnosis in Spinal Muscular Atrophy, visit www.mdedge.com/DiagnosisInSMA.

References

1. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732.
2. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625-635.
3. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose genereplacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722.
4. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856.

Click to Read 

With newly available disease-modifying therapies, the phenotype of spinal muscular atrophy (SMA) is rapidly changing, and affected individuals are living longer, healthier lives.^1-4 This supplement discusses therapeutic strategies, FDA-approved treatment options, and the SMA drug pipeline.

Click to Read

To access Part 1 of the SMA Spotlight series, The Urgent Need for Early Diagnosis in Spinal Muscular Atrophy, visit www.mdedge.com/DiagnosisInSMA.

References

1. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732.
2. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625-635.
3. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose genereplacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722.
4. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856.

Read more

Our sixth annual Rare Neurological Disease Special Report is our biggest issue yet. It is very gratifying to know we are part of the rare disease community and witness to some of the exciting developments that are transforming this field. There are many newly approved therapies highlighted in the articles in this issue, as well as brief profiles of a number of research groups within the NIH’s Rare Diseases Clinical Research Network  and an intriguing profile of how the Netflix show Diagnosis used crowdsourcing to solve medical mysteries, many of which involved rare neurologic conditions. That’s just a sampling of what this issue has to offer. There are too many articles to mention each one, but I hope you take the time to read the entire issue.

—Glenn S. Williams, vice president, group editor, Neurology Reviews

Read more

Read more

Our sixth annual Rare Neurological Disease Special Report is our biggest issue yet. It is very gratifying to know we are part of the rare disease community and witness to some of the exciting developments that are transforming this field. There are many newly approved therapies highlighted in the articles in this issue, as well as brief profiles of a number of research groups within the NIH’s Rare Diseases Clinical Research Network  and an intriguing profile of how the Netflix show Diagnosis used crowdsourcing to solve medical mysteries, many of which involved rare neurologic conditions. That’s just a sampling of what this issue has to offer. There are too many articles to mention each one, but I hope you take the time to read the entire issue.

—Glenn S. Williams, vice president, group editor, Neurology Reviews

Read more

Read more

Our sixth annual Rare Neurological Disease Special Report is our biggest issue yet. It is very gratifying to know we are part of the rare disease community and witness to some of the exciting developments that are transforming this field. There are many newly approved therapies highlighted in the articles in this issue, as well as brief profiles of a number of research groups within the NIH’s Rare Diseases Clinical Research Network  and an intriguing profile of how the Netflix show Diagnosis used crowdsourcing to solve medical mysteries, many of which involved rare neurologic conditions. That’s just a sampling of what this issue has to offer. There are too many articles to mention each one, but I hope you take the time to read the entire issue.

—Glenn S. Williams, vice president, group editor, Neurology Reviews

Read more

• Understanding the obesity risk in patients with NVAF
• Challenges of anticoagulation with warfarin in patients with obesity
• NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

• Understanding the obesity risk in patients with NVAF
• Challenges of anticoagulation with warfarin in patients with obesity
• NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

• Understanding the obesity risk in patients with NVAF
• Challenges of anticoagulation with warfarin in patients with obesity
• NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

• Understanding the obesity risk in patients with NVAF
• Challenges of anticoagulation with warfarin in patients with obesity
• NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

• Understanding the obesity risk in patients with NVAF
• Challenges of anticoagulation with warfarin in patients with obesity
• NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

• Understanding the obesity risk in patients with NVAF
• Challenges of anticoagulation with warfarin in patients with obesity
• NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

In this issue of CHEST Clinical Perspectives, CHEST is undertaking primary research with pulmonologists to assess perceptions regarding curative intent when it comes to treating patients diagnosed with stage III NSCLC. The objectives of this research are to:

• Understand the role of the pulmonologist in diagnostic process, including diagnosis, cell type, staging.

• Understand the process of referral for treatment of patients with stage III NSCLC diagnosed in pulmonary practices, including frequency of referral to oncology and barriers to referral.

• Understand knowledge levels about stage III NSCLC, including differences between patients with stage III and stage IV and how that impacts referral for treatment.

• Understand the extent to which pulmonologists consider stage III patients to be in a curative state.

Read the full issue

In this issue of CHEST Clinical Perspectives, CHEST is undertaking primary research with pulmonologists to assess perceptions regarding curative intent when it comes to treating patients diagnosed with stage III NSCLC. The objectives of this research are to:

• Understand the role of the pulmonologist in diagnostic process, including diagnosis, cell type, staging.

• Understand the process of referral for treatment of patients with stage III NSCLC diagnosed in pulmonary practices, including frequency of referral to oncology and barriers to referral.

• Understand knowledge levels about stage III NSCLC, including differences between patients with stage III and stage IV and how that impacts referral for treatment.

• Understand the extent to which pulmonologists consider stage III patients to be in a curative state.

Read the full issue

In this issue of CHEST Clinical Perspectives, CHEST is undertaking primary research with pulmonologists to assess perceptions regarding curative intent when it comes to treating patients diagnosed with stage III NSCLC. The objectives of this research are to:

• Understand the role of the pulmonologist in diagnostic process, including diagnosis, cell type, staging.

• Understand the process of referral for treatment of patients with stage III NSCLC diagnosed in pulmonary practices, including frequency of referral to oncology and barriers to referral.

• Understand knowledge levels about stage III NSCLC, including differences between patients with stage III and stage IV and how that impacts referral for treatment.

• Understand the extent to which pulmonologists consider stage III patients to be in a curative state.

Read the full issue